Articles On Bionomics (ASX:BNO)

Title Source Codes Date
Closing Bell: Tech stocks lead the way as ASX snaps two-day losing streak

It was a fairly turbulent night on global markets, but the ASX 200 put in a fairly solid day of trade on Thursday to snap a two-day losing streak. Risk-on sentiment held sway as the microcap Emerging Companies index rose more than 1%, while...

Stockhead BNO 1 week ago
These 3 ASX Healthcare shares have soared over 10% today

The broad Australian indices have started the day off in the red as the market resets from a number of stirrups this week. The S&P/ASX 200 index (ASX: XJO) has clipped 0.37% lower today and sits at 7,343 points, whereas the S&P/AS...

Motley Fool BNO 3 weeks ago
Bionomics expands clinical trial plan for BNC210

Clinical-stage biopharmaceutical company Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute Social Anxiety Disorder.

BiotechDispatch BNO 4 weeks ago
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder Phase 2 clinical trial on target to start by end of 2021 and expected to read out to...

FNArena BNO 4 weeks ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead BNO 1 month ago
Closing Bell: Energy shares push ASX higher

It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w...

Stockhead BNO 1 month ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead BNO 2 months ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead BNO 2 months ago
Bionomics announces plans for US initial public offering

Bionomics (ASX:BNO) has announced that it plans to conduct a registered initial public offering of shares in the US and a listing on Nasdaq.

BiotechDispatch BNO 2 months ago
Bionomics Announces Plans to Conduct U.S. Initial Public Offering

ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offerin...

FNArena BNO 2 months ago
These stocks kept the ASX buzzing today

The S&P/ASX200 closed up Monday, gaining 98.80 points or 1.34% to 7,491.40 and setting a new 100-day high. Over the last five days, the index has gained 1.31% and is currently 0.20% off of its 52-week high. All 11 sectors ended higher...

Kalkine Media BNO 2 months ago
ASX Health Stocks: Hydrix implants world’s first Guardian heart attack alert system

The biggest winner in health stocks today was Hydrix (ASX:HYD) – up 9.68% off the back of news that Angel Medical Systems had completed its first commercial implantation in the US of the Guardian device – a cardiac detection monitor and pat...

Stockhead BNO 2 months ago
10 at 10: These ASX stocks have attracted the most investor focus this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead BNO 2 months ago
10 at 10: These ASX stocks are keeping their eye on the prize this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead BNO 2 months ago
Closing Bell: Aussie shares rebound as ASX investors buy the dip

Aussie shares rebounded today following rises in the US and Europe overnight, after having fallen for the previous two days. The ASX 200 regained 0.78%, with all 11 sectors in the green except for Industrials and IT. Healthcare and financia...

Stockhead BNO 2 months ago
10 at 10: These ASX stocks are experiencing zero gravity this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead BNO 2 months ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead BNO 2 months ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead BNO 3 months ago
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

ADELAIDE, Australia, July 6, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase 2b trial (the ATTUNE...

FNArena BNO 3 months ago
ASX edges higher ahead of RBA meeting; energy, material stocks lead 

Summary The S&P/ASX200 traded up by 12.60 points or 0.17% at 7,327.60 by Tuesday afternoon. All the “big four” banks were trading higher ahead of the monetary policy announcement by the Reserve Bank. The energy sector was the best...

Kalkine Media BNO 3 months ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead BNO 4 months ago
Invion led a group of ASX cancer stocks up after promising news

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Stockhead BNO 4 months ago
Bionomics expands study of BNC210 to include social anxiety disorder

Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute treatment of Social Anxiety Disorder while progressing toward the start of its planned Phase 2b trial i...

BiotechDispatch BNO 5 months ago
Bionomics BNC210 Expansion into Social Anxiety Disorder

Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research sele...

FNArena BNO 5 months ago
Here’s why Bionomics (ASX:BNO) shares were trending on the ASX today

Summary Biopharmaceutical company Bionomics Limited will expand its product pipeline for the treatment of Social Anxiety Disorder (SAD). The Company disclosed that the rapid oral absorption of the novel tablet formulation of BNC210 is...

Kalkine Media BNO 5 months ago
Market highlights and 5 ASX small caps to watch on Monday

Wall Street dropped on Friday, but still positive in April On Friday trading, the Dow Jones fell 0.54%, S&P 500 was down 0.72%, while tech heavy NASDAQ also dropped 0.85%. But the market was still able to hold on to its monthly gains, w...

Stockhead BNO 5 months ago
Capital Raisings Recap: Nearly $10 billion has already been raised in 2021

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Stockhead BNO 5 months ago
A glance at 2 ASX penny shares  - MGC Pharmaceuticals and archTIS

Summary Australian players MGC Pharmaceuticals and ArchTIS limited were under the spotlight following recent crucial developments. Biopharma player MGC Pharma announced the acquisition of MediCaNL that is likely to deliver cost savings...

Kalkine Media BNO 5 months ago
Trading Places: Tolga Kumova has settled on a uranium play – Valor Resources (ASX:VAL)

If you want to know which ASX stocks fund managers and famous investors are putting their money into we’ve been keeping track of substantial holder buys (and sells). Trading Places is Stockhead’s recap of the substantial holder movements am...

Stockhead BNO 5 months ago
Bionomics Successfully Completes A$22.9 million Equity Raise

ADELAIDE, Australia, April 9, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 (Entitlement Offer) and concurr...

FNArena BNO 6 months ago
Market remains volatile in days trade, recoups post lunch

Source: wutzkohphoto, Shutterstock Today, the Australian market traded in the green. The benchmark index ASX 200 initially spiked, and after gaining significant points, it fell sharply towards the afternoon but later on bounced back on the...

Kalkine Media BNO 6 months ago
Closing Bell: Today’s biggest small cap movers on the ASX

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Stockhead BNO 7 months ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead BNO 7 months ago
Closing Bell: Today’s biggest small cap movers on the ASX

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Stockhead BNO 7 months ago
Up almost 1000% in 1 year, the Bionomics (ASX:BNO) share price moves higher

The Bionomics Ltd (ASX: BNO) share price is in positive territory today after announcing a non-renounceable entitlement offer. During mid-afternoon trade, the clinical-stage biopharmaceutical company’s shares are up 3.5% to 30 cents. This...

Motley Fool BNO 7 months ago
Bionomics' positive pharmacokinec results confirms it can begin second Phase 2 study to treat PTSD

Proactive Investors BNO 7 months ago
Bionomics' positive pharmacokinetic results confirms it can begin second Phase 2 study to treat PTSD

Proactive Investors BNO 7 months ago
5 ASX-listed biotech penny stocks to keep an eye on

Source: ShutterstockProfessional Summary Biotech penny stocks are extremely volatile, given the unpredictable nature of the biotechnology industry. Positive clinical developments and regulatory approvals for biotech penny players coul...

Kalkine Media BNO 7 months ago
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial

BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trial BNC210 Phase 2b PTSD trial on target for start in mid-2021 with final dose selected ADELAIDE, Australia, F...

FNArena BNO 7 months ago
Bionomics in collaboration with EmpathBio

Bionomics (ASX:BNO) has announced a Memorandum of Understanding with EmpathBio, the wholly-owned subsidiary of German-based CNS clinical development company atai Life Sciences.

BiotechDispatch BNO 8 months ago
Joint feasibility assessment of Bionomics’ BNC210 and EmpathBio’s MDMA derivative EMP-01 treatment regimen for PTSD

ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly...

FNArena BNO 8 months ago
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial

Commitments received for a placement of A$15,991,634 at A$0.145 per share Significant participation from North American and European institutional and sophisticated investors This capital raising enables proceeding with the Phase 2b PT...

FNArena BNO 8 months ago
Why the Bionomics (ASX:BNO) share price is climbing today

The Bionomics Ltd (ASX: BNO) share price continues to climb today after the company announced it had received commitments for a placement. At the time of writing, shares in the clinical-stage biopharmaceutical company are up 2.2% to 22.5 c...

Motley Fool BNO 8 months ago
Bionomics says treatment phase complete in BNC105 combination trial

Clinical-stage biopharmaceutical company Bionomics (ASX:BNO) has announced that all patients have completed their treatment phase in the MODULATE clinical trial.

BiotechDispatch BNO 8 months ago
Bionomics completes Phase 2 of MODULATE combination clinical trial for colorectal cancer

The MODULATE trial is evaluating new experimental approaches to immunotherapy treatment in colorectal cancer patients.

Proactive Investors BNO 8 months ago
Bionomics initiates 7-day dosing pharmacokinetic study of BNC210 tablets

The company’s lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor.

Proactive Investors BNO 9 months ago
What is Bionomics’ (ASX:BNO) 7-Day pharmacokinetic clinical trial all about?

Summary Bionomics initiates a 7-day, twice-daily dosing pharmacokinetic clinical trial. The company’s leading candidate, BNC210, would be used with a new solid dose tablet formulation on the volunteers. The result from the trial is ex...

Kalkine Media BNO 9 months ago
Carina Biotech teams up with Bionomics on CAR-T

Adelaide’s Carina Biotech has announced an agreement to create CAR-T cells targeted at a cancer stem cell marker that is abundant in solid tumours.

BiotechDispatch BNO 10 months ago
Why the Bionomics (ASX:BNO) share price surged 8% higher today

The Bionomics Ltd (ASX: BNO) share price has run higher today after the company announced it has entered an agreement to licence its oncology drug candidate, BNC101, to Carina Biotech. At the market’s close, the Bionomics share price had s...

Motley Fool BNO 10 months ago
Bionomics' completes institutional stage of capital raise

Bionomics (ASX:BNO) has announced the successful completion of the institutional component of its one for 12.54 pro-rata accelerated non‐renounceable entitlement offer.

BiotechDispatch BNO 1 year ago